Organon & Co. (OGN) KPIs and segments
Close on Nov 18, 2026Market cap $3.66BP/E 18.1Yield 2.44%
KPIs & segments
Operating metrics and segments that drive Organon's business
Organon's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nexplanon/Implanon NXT($M)2 | 200 | 230 | 201 | 210 | 223 | 240 | 248 | 259 | 243 | 242 | 220 | 231 | |
United States($M) | 127 | 129 | 127 | 124 | 146 | 163 | 176 | 175 | 172 | 171 | 153 | 154 | |
Intl($M) | 73 | 101 | 74 | 86 | 77 | 77 | 72 | 84 | 70 | 70 | 67 | 76 | |
Zetia($M)2 | 101 | 96 | 87 | 90 | 93 | 74 | 85 | 77 | 81 | 75 | 84 | 69 | |
Intl($M) | 100 | 95 | 86 | 89 | 91 | 72 | 84 | 75 | 80 | 73 | 82 | 66 | |
United States($M) | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | |
Other($M)2 | 93 | 96 | 87 | 85 | 88 | 87 | 78 | 87 | 84 | 72 | 29 | 79 | |
Intl($M) | 91 | 94 | 85 | 82 | 86 | 85 | 76 | 85 | 80 | 69 | 29 | 77 | |
United States($M) | 0 | 0 | 0 | 4 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | |
Hadlima($M)2 | 86 | 79 | 67 | 69 | 63 | 50 | 47 | 44 | 40 | 28 | 30 | 24 | |
United States($M) | 62 | 55 | 51 | 50 | 47 | 36 | 33 | 33 | 29 | 20 | 22 | 15 | |
Intl($M) | 24 | 24 | 16 | 18 | 16 | 14 | 14 | 11 | 11 | 8 | 8 | 8 | |
Atozet($M)2 | 85 | 80 | 85 | 67 | 95 | 86 | 77 | 77 | 125 | 140 | 132 | 122 | |
Intl($M) | 85 | 80 | 85 | 67 | 95 | 86 | 77 | 77 | 125 | 140 | 132 | 122 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other Non-Opiod Pain, Bone and Dermatology($M)2 | 75 | 79 | 68 | 72 | 80 | 80 | 68 | 68 | 74 | 78 | 72 | 68 | |
Intl($M) | 71 | 75 | 65 | 68 | 75 | 76 | 65 | 67 | 69 | 73 | 68 | 65 | |
United States($M) | 3 | 4 | 3 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 3 | |
Arcoxia($M)2 | 69 | 69 | 59 | 70 | 71 | 63 | 62 | 59 | 69 | 68 | 75 | 50 | |
Intl($M) | 69 | 69 | 59 | 70 | 71 | 63 | 62 | 59 | 69 | 68 | 75 | 50 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Follistim AQ($M)2 | 67 | 59 | 61 | 58 | 64 | 74 | 69 | 66 | 63 | 62 | 46 | 83 | |
Intl($M) | 35 | 43 | 39 | 35 | 40 | 43 | 34 | 39 | 37 | 40 | 35 | 31 | |
United States($M) | 32 | 17 | 21 | 23 | 24 | 30 | 35 | 25 | 26 | 22 | 11 | 51 | |
Renflexis($M)2 | 67 | 65 | 57 | 61 | 70 | 63 | 57 | 64 | 72 | 69 | 69 | 77 | |
United States($M) | 46 | 44 | 42 | 42 | 51 | 46 | 44 | 52 | 56 | 56 | 55 | 62 | |
Intl($M) | 21 | 21 | 15 | 20 | 19 | 17 | 12 | 12 | 16 | 13 | 14 | 14 | |
Nasonex($M)2 | 65 | 58 | 65 | 65 | 60 | 66 | 72 | 76 | 63 | 60 | 77 | 69 | |
Intl($M) | 65 | 58 | 65 | 64 | 60 | 66 | 71 | 76 | 63 | 60 | 77 | 69 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Emgality($M)2 | 59 | 54 | 54 | 49 | 51 | 42 | 32 | 38 | 29 | 30 | 10 | 0 | |
Intl($M) | 59 | 54 | 54 | 49 | 51 | 42 | 32 | 38 | 29 | 30 | 10 | 0 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Cozaar/Hyzaar($M)2 | 51 | 50 | 57 | 53 | 55 | 56 | 55 | 57 | 59 | 60 | 67 | 56 | |
Intl($M) | 49 | 48 | 55 | 51 | 53 | 54 | 53 | 55 | 57 | 58 | 65 | 55 | |
United States($M) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | |
Other Women's Health($M)2 | 45 | 45 | 46 | 46 | 43 | 42 | 43 | 39 | 40 | 34 | 43 | 41 | |
Intl($M) | 29 | 29 | 30 | 29 | 26 | 27 | 27 | 26 | 28 | 23 | 28 | 27 | |
United States($M) | 14 | 15 | 17 | 18 | 17 | 14 | 15 | 15 | 14 | 13 | 15 | 16 | |
Singulair($M)2 | 45 | 48 | 40 | 59 | 53 | 66 | 74 | 84 | 85 | 93 | 98 | 114 | |
Intl($M) | 43 | 46 | 38 | 57 | 51 | 64 | 72 | 82 | 83 | 90 | 95 | 111 | |
United States($M) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | |
Diprospan($M)2 | 42 | 44 | 35 | 38 | 41 | 41 | 30 | 37 | 37 | 37 | 29 | 33 | |
Intl($M) | 42 | 44 | 35 | 38 | 41 | 41 | 30 | 37 | 37 | 37 | 29 | 33 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Vtama($M)2 | 42 | 35 | 25 | 39 | 34 | 31 | 24 | 12 | 0 | 0 | 0 | ||
United States($M) | 38 | 34 | 23 | 31 | 31 | 29 | 20 | 10 | 0 | 0 | 0 | ||
Intl($M) | 4 | 1 | 2 | 8 | 3 | 2 | 4 | 1 | 0 | 0 | 0 | ||
Propecia($M)2 | 41 | 36 | 30 | 28 | 33 | 32 | 26 | 32 | 28 | 28 | 23 | 33 | |
Intl($M) | 40 | 34 | 28 | 26 | 31 | 30 | 24 | 31 | 27 | 27 | 21 | 32 | |
United States($M) | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |
Dulera($M)2 | 35 | 41 | 35 | 35 | 34 | 41 | 43 | 52 | 48 | 47 | 56 | 50 | |
United States($M) | 25 | 30 | 23 | 24 | 24 | 32 | 34 | 42 | 38 | 39 | 43 | 40 | |
Intl($M) | 10 | 11 | 12 | 11 | 10 | 9 | 10 | 11 | 10 | 8 | 13 | 10 | |
Other Cardiovascular($M)2 | 35 | 25 | 28 | 28 | 33 | 34 | 30 | 34 | 29 | 32 | 38 | 27 | |
Intl($M) | 34 | 23 | 27 | 27 | 33 | 33 | 30 | 33 | 27 | 31 | 37 | 26 | |
United States($M) | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |
Fosamax($M)2 | 28 | 25 | 29 | 36 | 40 | 34 | 33 | 39 | 38 | 35 | 40 | 36 | |
Intl($M) | 28 | 24 | 29 | 35 | 40 | 34 | 32 | 38 | 37 | 34 | 38 | 35 | |
United States($M) | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | |
Marvelon/Mercilon($M)2 | 28 | 32 | 26 | 24 | 31 | 33 | 39 | 31 | 29 | 41 | 33 | 37 | |
Intl($M) | 28 | 32 | 26 | 24 | 31 | 33 | 39 | 31 | 29 | 41 | 33 | 37 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Nuva Ring($M)2 | 25 | 27 | 24 | 16 | 26 | 28 | 22 | 25 | 23 | 29 | 38 | 39 | |
Intl($M) | 19 | 18 | 18 | 18 | 17 | 21 | 16 | 18 | 17 | 19 | 22 | 19 | |
United States($M) | 6 | 9 | 6 | 9 | 7 | 6 | 6 | 7 | 10 | 16 | 20 | ||
Vytorin($M)2 | 25 | 21 | 21 | 25 | 25 | 27 | 23 | 26 | 26 | 28 | 28 | 29 | |
Intl($M) | 24 | 20 | 20 | 24 | 25 | 26 | 22 | 24 | 25 | 26 | 27 | 29 | |
United States($M) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | |
Ganirelix Acetate Injection($M)2 | 24 | 26 | 26 | 24 | 22 | 27 | 27 | 27 | 26 | 27 | 29 | 22 | |
Intl($M) | 21 | 24 | 24 | 22 | 19 | 25 | 23 | 24 | 20 | 22 | 23 | 17 | |
United States($M) | 4 | 2 | 2 | 2 | 3 | 3 | 5 | 4 | 5 | 5 | 6 | 4 | |
Bildyos/Bilprevda($M)2 | 24 | 19 | 3 | 0 | |||||||||
United States($M) | 17 | 14 | 3 | 0 | |||||||||
Intl($M) | 7 | 5 | 0 | 0 | |||||||||
Clarinex($M)2 | 23 | 30 | 31 | 30 | 25 | 34 | 34 | 27 | 27 | 35 | 37 | 29 | |
Intl($M) | 23 | 30 | 30 | 29 | 25 | 33 | 34 | 28 | 26 | 35 | 36 | 29 | |
United States($M) | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | |
Proscar($M)2 | 22 | 20 | 26 | 24 | 27 | 22 | 24 | 22 | 23 | 23 | 26 | 20 | |
Intl($M) | 22 | 20 | 26 | 23 | 27 | 22 | 24 | 22 | 23 | 23 | 26 | 20 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Brenzys($M)2 | 22 | 14 | 20 | 21 | 23 | 22 | 14 | 14 | 27 | 12 | 24 | 28 | |
Intl($M) | 22 | 14 | 20 | 21 | 23 | 22 | 14 | 14 | 27 | 12 | 24 | 28 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Other Respiratory($M)2 | 14 | 18 | 12 | 12 | 12 | 14 | 13 | 18 | 14 | 13 | 9 | 12 | |
United States($M) | 11 | 16 | 11 | 10 | 9 | 11 | 10 | 12 | 11 | 8 | 7 | 7 | |
Intl($M) | 3 | 1 | 1 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | |
Other Biosimilars($M)2 | 13 | 12 | 24 | 14 | 6 | 7 | 5 | 6 | 7 | ||||
United States($M) | 10 | 10 | 11 | 11 | 3 | 3 | 0 | 0 | 0 | ||||
Intl($M) | 2 | 2 | 13 | 3 | 3 | 4 | 5 | 6 | 7 | ||||
Ontruzant($M)2 | 7 | 6 | 5 | 19 | 31 | 31 | 18 | 34 | 20 | 48 | 39 | 62 | |
United States($M) | 4 | 5 | 4 | 3 | 4 | 5 | 4 | 6 | 5 | 10 | 8 | 10 | |
Intl($M) | 3 | 1 | 1 | 16 | 28 | 26 | 14 | 28 | 15 | 38 | 31 | 52 | |
Rosuzet($M)2 | 5 | 5 | 6 | 8 | 6 | 6 | 4 | 13 | 11 | 9 | 16 | 18 | |
Intl($M) | 5 | 5 | 6 | 8 | 6 | 6 | 4 | 13 | 11 | 9 | 16 | 18 | |
United States($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Jada($M)2 | 0 | 0 | 5 | 20 | 20 | 18 | 15 | 18 | 16 | 14 | 13 | 12 | |
Intl($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
United States($M) | 0 | 0 | 5 | 20 | 20 | 18 | 15 | 18 | 15 | 14 | 13 | 13 | |
Earlier reporting (last reported 2025)2 | |||||||||||||
Intl($M) | 1,163 | 1,160 | 1,102 | 1,135 | 1,196 | 1,180 | 1,101 | 1,176 | 1,184 | 1,219 | 1,251 | 1,187 | |
Europe and Canada($M) | 417 | 432 | 412 | 406 | 417 | 419 | 376 | 420 | 436 | 457 | 450 | 414 | |
United States($M) | 411 | 398 | 358 | 372 | 406 | 414 | 412 | 416 | 398 | 388 | 371 | 411 | |
Latin America, Middle East, Russia, and Africa($M) | 269 | 269 | 247 | 262 | 286 | 285 | 240 | 266 | 243 | 251 | 274 | 278 | |
Asia Pacific and Japan($M) | 234 | 232 | 226 | 248 | 251 | 250 | 251 | 244 | 260 | 260 | 287 | 260 | |
China($M) | 226 | 208 | 194 | 202 | 219 | 204 | 204 | 213 | 212 | 216 | 206 | 203 | |
Other($M) | 17 | 19 | 23 | 17 | 23 | 22 | 30 | 33 | 33 | 35 | 34 | 32 | |
Manufacturing facilities | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | ||||
18 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-30.
See a number that looks wrong?